Latest stories on GALT
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
TipRanks58 · neutralgeneral
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Business Insider63 · neutralgeneral
GALECTIN THERAPEUTICS INC (GALT) files 8-K
SEC 8-K50 · neutralgeneral
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Seeking Alpha67 · bullishproduct/pr
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Stocktwits News73 · bullishproduct/pr
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans
Morningstar73 · bullishproduct/pr
Galectin, FDA agree on late-stage trial design for MASH therapy
Seeking Alpha42 · neutralproduct/pr
Galectin Advances Belapectin to Phase 3 After FDA Alignment
TipRanks63 · neutralproduct/pr
GALECTIN THERAPEUTICS INC (GALT) files 8-K
SEC 8-K50 · neutralgeneral
Galectin Therapeutics GAAP EPS of -$0.08 misses by $0.02
Seeking Alpha34 · bearishearnings